PURPOSE
The need to increase the number oncology clinical trials with sufficient enrollments is a well-known issue, particularly for trials targeting therapeutic applications. It is critical to identify early predictors of eventual study accrual achievement.
EXPERIMENTAL DESIGN
All nonpediatric phase I, I/II, II, and III therapeutic studies supported by the National Cancer Institute Cancer Th...